BioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017

Tuesday, March 7, 2017 9:00 AM UTC

MAINZ, Germany, March 07, 2017 -- BioNTech AG, a fully-integrated biotechnology company pioneering individualized cancer immunotherapy, today announced that it will present interim data from an ongoing Phase I/II clinical trial of its Lipo-MERIT vaccine in patients with malignant melanoma at the 2017 Annual Meeting of the American Association for Cancer Research (AACR), taking place April 1 – 5 in Washington, DC. This is the first example of a clinically applied systemic mRNA-based cancer immunotherapy.

Permanent Abstract Number: CT034

Poster:	“A First-in-Human Phase I/II Clinical Trial Assessing Novel mRNA-lipoplex Nanoparticles for
	Potent Melanoma Immunotherapy”
Date:	Monday, April 3, 2017
Session:	PO.CT01 - Phase I Clinical Trials in Progress
Time:	8:00AM – 12:00PM Eastern Daylight Time
Location:	Poster Section 33

The Phase I/II dose escalation Lipo-MERIT trial (NCT02410733) in melanoma patients assesses the safety and tolerability as well as the potency of inducing antigen-specific immune responses of the first systemic mRNA vaccine to be developed based on BioNTech’s mRNA nanoparticle immunotherapy platform.

About BioNTech AG

BioNTech is Europe’s largest privately held biopharmaceutical company pioneering the development of individualized therapies for cancer and other diseases. The company combines all building blocks of individualized immunotherapy under one roof – from diagnostics and drug development to manufacturing. Its cutting-edge technologies range from individualized mRNA-based medicines through innovative chimeric antigen receptors and T-cell receptor-based products to novel checkpoint immunomodulators. BioNTech’s approach is validated by five top-tier corporate partnerships with Genentech, Genmab, Eli Lilly and Company, Sanofi and Bayer Animal Health. Founded in 2008, BioNTech’s shareholders include the MIG Fonds, Salvia and the Strüngmann Family Office, with the Strüngmann Family Office as the majority shareholder.

More information about BioNTech is available at www.biontech.de.

For meeting requests or further information, please contact:

General Inquiries:
BioNTech AG 
Regina Jehle
Tel: +49 6131 9084 1273
Email: [email protected]

US Media & Investors:
ICR Healthcare
James Heins / Stephanie Carrington
Tel: +1 203 682 8251
Tel: +1 646 277 1282
Email: [email protected]
Email: [email protected]

International Media & Investor Inquiries:
akampion
Dr. Ludger Wess / Ines-Regina Buth
Tel: +49 40 8816 5964
Tel: +49 30 2363 2768
Email: [email protected]

Editor's Picks

Breathing through your nose when you exercise may make your runs easier

Entrepreneurs are facing a mental health crisis — here's how to help them

Are fish oil supplements as healthy as we think? And is eating fish better?

Will AI kill our creativity? It could – if we don’t start to value and protect the traits that make us human

Does AI have a right to free speech? Only if it supports our right to free thought

How can I lower my cholesterol? Do supplements work? How about psyllium or probiotics?

Why we need to set limits on sperm donation

Aging with a healthy brain: How lifestyle changes could help prevent up to 40% of dementia cases

Seven techniques to avoid weight regain, approved by experts

BioNTech to Present Interim Phase I/II Data for Investigational mRNA Vaccine in Melanoma Patients at AACR Annual Meeting 2017

Editor's Picks

Welcome to EconoTimes